FDA Approves First CAR-T Cell Therapy

Membership Ticker

Mother Jones’ union co-chair Patrick Caldwell connects the dots: Facebook's decision to throttle our content cost Mother Jones at least $400,000—the same amount we had to cut from our payroll this year. Please read his post, and if you can, chip in to help us finish our fall fundraising drive strong and hit our big goal by Saturday's deadline.

$350,000

We still need to raise about 400,000

Johann Groder/APA Picturedesk via ZUMA

For indispensable reporting on the coronavirus crisis, the election, and more, subscribe to the Mother Jones Daily newsletter.

Progress:

The Food and Drug Administration on Wednesday approved the first-ever treatment that genetically alters a patient’s own cells to fight cancer, a milestone that is expected to transform treatment in the coming years….The therapy, marketed as Kymriah and made by Novartis, was approved for children and young adults for an aggressive type of leukemia — B-cell acute lymphoblastic leukemia….The treatment was originally developed by researchers at the University of Pennsylvania and licensed to Novartis. It was identified in previous reports as CAR-T cell therapy, CTL019 or tisagenlecleucel.

Hooray! Let’s do multiple myeloma next! This therapy costs half a million bucks or so, but as long as someone else is paying for it I figure I’m worth it.